- Hayworth Cancer Center
- Carolina Regional Heart Center
- Diabetes Self-Care Management Center
- The Emergency Center
- The Fitness Center at High Point Regional
- The Fitness Center at Kernersville
- Heart Strides
- Behavioral Health
Meningococcal Vaccine(MCV4 Vaccine)
by
Krisha McCoy, MS What Is Meningococcal Disease?Neisseria meningitidis is a bacteria that can cause infections in the body. One area this bacteria can infect is the meninges. The meninges is the membrane that surrounds the brain and spinal cord. A bacterial infection of the meninges, called bacterial meningitis, can cause death within hours. This bacteria can also cause infections in the blood. The disease is usually spread by direct contact with discharge from the mouth or throat of an infected person (eg, kissing). The disease is most common in:
About 1,200 people in the US develop the disease each year. Approximately 10%-15% of these people die. Another 11%-19% lose their arms or legs, become deaf, have nervous system problems, become intellectual disabled, or suffer seizures or strokes. Symptoms of meningitis include:
Symptoms in newborn and infants can be hard to notice. These may include:
Treatment may include:
What Is the Meningococcal Vaccine?There are two meningococcal vaccines available in the US:
Both vaccines are made from parts of the meningococcal bacteria. They do not contain live bacteria. Who Should Get Vaccinated and When? TOPRoutine VaccinationThe MCV4 vaccine is routinely given to children aged 11-12 years old with a booster dose given at age 16 years. Three doses are given to teens (11-18 years old) who have HIV:
Teens who receive the vaccine late follow this schedule:
Vaccination for People at Increased RiskThe following groups of people need to be vaccinated because they have an increased risk of meningitis:
Young children aged 9-23 months and others who have certain conditions need to be given two doses in order to be fully protected. People who are at high risk will need a booster dose every five years. What Are the Risks Associated With the Meningococcal Vaccine? TOPThe meningococcal vaccine, like all vaccines, has the potential to cause serious problems, such as severe allergic reactions. The risk of the vaccine causing serious harm or death is extremely small. Mild problems associated with the vaccine include redness or pain at the injection site or a fever. Who Should Not Get Vaccinated? TOPIf you have the following conditions, you should not get the vaccine:
The vaccines may be given to pregnant women. However, the MCV4 vaccine has not been extensively studied in pregnant women. It should be used only if it is clearly needed. What Other Ways Can Meningococcal Disease Be Prevented Besides Vaccination? TOPPreventive antibiotics may be given to people in close contact with an infected person, such as:
Quitting smoking may also reduce the risk of meningococcal disease. What Happens in the Event of an Outbreak? TOPIn the event of an outbreak, close contacts of infected people and people at increased risk should get the vaccine. Antibiotics may be recommended for people in close contact. WHERE CAN I GET MORE INFORMATION? References:
Bacterial meningitis in adults. EBSCO DynaMed website. Available at:
http://www.ebscohost.com/dynamed
. Updated November 15, 2012. Accessed November 29, 2012.
Bacterial meningitis in infants and children. EBSCO DynaMed website. Available at:
http://www.ebscohost.com/dynamed
. Updated November 21, 2012. Accessed November 29, 2012.
Baker CJ, Pickerling LK, Chilton L, et al. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2011.
Ann Intern Med.
2011;154(3):168-173.
Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years—United States, 2011.
MMWR.
2011;60(5).
Deasy A, Read RC. Challenges for development of meningococcal vaccines in infants and children.
Expert Rev Vaccines.
2011;10(3):335-343.
Honish L, Soskolne CL, Senthilselvan A, Houston S. Modifiable risk factors for
invasive meningococcal disease during an Edmonton, Alberta outbreak, 1999-2002.
Can J Public Health.
2008;99(1):46-51.
Huttunen R, Heikkinen T, Syrjänen J. Smoking and the outcome of infection.
J
Intern Med.
2011;269(3):258-269.
Menactra. DailyMed website. Available at:
http://dailymed.nl...
. Updated December 2011. Accessed November 29, 2012.
Meningitis questions and answers. US Centers for Disease Control and Prevention website. Available at:
http://www.cdc.gov/meningococcal/about/index.html
. Updated March 15, 2012. Accessed November 30, 2012.
Meningococcal disease. Centers for Disease Control and Prevention website. Available at:
http://www.cdc.gov/meningococcal/about/symptoms.html
. Updated March 15, 2012. Accessed November 29, 2012.
Meningococcal disease. DermNet NZ website. Available at:
http://dermnetnz.org/bacterial/meningococcal-disease.html
. Updated June 29, 2011. Accessed November 30, 2012.
Meningococcal disease vaccine. Immunization Saves Lives website. Available at:
http://www.vaccineinformation.org/menin/qandavax.asp
. Accessed November 29, 2012.
Meningococcal vaccination. US Centers for Disease Control and Prevention website. Available at:
http://www.cdc.gov/vaccines/vpd-vac/mening/default.htm
. Accessed November 30, 2012.
Meningococcal vaccines: What you need to know. Centers for Disease Control and Prevention website. Available at:
http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-mening.pdf
. Updated October 14, 2011. Accessed November 29, 2012.
Recommended immunization schedules for persons aged 0-6 years—United States, 2012. Centers for Disease Control and Prevention website. Available at:
http://www.cdc.gov...
.
Published December 23, 2011. Accessed November 30, 2012.
Recommended immunization schedules for persons aged 7-18 years—United States, 2012. Centers for Disease Control and Prevention website. Available at:
http://www.cdc.gov...
.
Accessed November 30, 2012.
Vaccine information statement: meningococcal vaccines. US Centers for Disease Control and Prevention website. Available at:
http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-mening.pdf
. Updated October 14, 2011. Accessed November 30, 2012.
Vaccine information statements. Immunization Action Coalition website. Available at:
http://www.immunize.org/vis/
. Accessed November 30, 2012.
1/31/2008 DynaMed's Systematic Literature Surveillance
http://www.ebscohost.com/dynamed/what.php
: Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years—United States, 2008.
MMWR
.
2008;57;Q1-Q4. Centers for Disease Control and Prevention, MMWR website. Available at:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5701a8.htm
.
Updated January 10, 2008. Accessed January 28, 2008.
10/6/2009 DynaMed's Systematic Literature Surveillance
http://www.ebscohost.com/dynamed/what.php
: Centers for Disease Control and Prevention. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease.
MMWR
.
2009;58(37):1042-1043. Centers for Disease Control and Prevention, MMWR website. Available at:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5837a4.htm
.
Published September 25, 2009. Accessed October 2, 2009.
12/16/2011 DynaMed's Systematic Literature Surveillance
http://www.ebscohost.com/dynamed/what.php
: Centers for Disease Control and Prevention (CDC). Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease.
MMWR Morb Mortal Wkly Rep.
2011;60(40):1391-1392.
Last reviewed November 2012 by Brian Randall, MD Last Updated: 11/26/2012 | |




